The Pharmaceutical War of Attrition: GLP-1, Oncology and the Infrastructure of Patient Access
Archive report from 11 May 2026. The era of the single blockbuster drug is over. We looked at the new battlegrounds in obesity drugs, cancer and patient access.
Research lead: Denys Zavertany
This archive report on pharma stocks was first published on 11 May 2026. Prices, figures and our view are as they stood that day, before our July 2026 Research Standard. How the view has played out since is tracked on our Track Record page.
In the first quarter of 2026 Eli Lilly's revenue rose 56% to $19.8 billion, driven by Mounjaro and Zepbound, while Novo Nordisk's reported growth was flattered by a one-off item. Oral obesity pills, cancer drugs and control of patient access are now where drug makers compete. The report maps those battlegrounds and what they mean for the leaders.
Already have an account? Log in
Continue with a free trial
Get full access to our independent research for 7 days.
Start free trialOr read the Quick Explanation. It is free
Related · same theme
Dismantling the Fed Put: The Warsh Regime and the Capital Preservation Playbook
11 Jul · How This Industry Works
The Last Mile of Medicine: Bridging Medical Science and Shareholder Value
7 Jul · How This Industry Works
The 90 Basis Point Bet: Auditing Molina’s Path to $25 EPS by 2029
1 Jun · How This Industry Works
Educational content only. Not investment advice.